Prof. Andrew JS Coats, Chairman of the Board of Directors. Prof. Coats’ main interest is Heart Failure. From Feb 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as CEO of the Norwich Research and Innovation Park, Deputy Vice-Chancellor and Dean of Medicine of the University of Sydney, Head of Cardiology of Imperial College, London and Associate Medical Director and Director of Cardiology of the Royal Brompton and Harefield Hospitals, London. Andrew studied Medicine at Oxford and Cambridge. He has published over 20 patents and more than 650 full research papers and more than 100,000 career citations, with a personal H-index of 135. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and currently serves as its president (2020-2022).
Frank Ahmann, President & CEO, is a medical device and biotech industry executive focused on developing technologies and organizations in the cardiovascular field. Collaborating with a network of physicians, he led the foundation of MateraCor and Nazzano Devices, Inc., a start-up to prevent heart disease in cancer patients. He is also a close advisor to Recardio, Inc., a clinical stage company with a drug candidate for AMI. Previously, as President and CEO of LoneStar Heart, he led the development of an implantable device for advanced heart failure from concept to proof of clinical safety and efficacy. Prior to that, he spent 10 years in executive positions in Europe and North America at Baxter International’s Biotech Group and Cardiovascular Group (now Edwards LifeSciences). Frank holds a BBA with Honors from University of Texas at Austin and an MBA from Columbia University Graduate School of Business in New York City.
Juliana Elstad, Director, is a CEO, entrepreneur, and advisor with over 20 years of experience identifying opportunities for growth and delivering success in small startup to multi-billion dollar environments. As founder and CEO of Impleo Medical, Ms. Elstad has raised investments and led the company from inception to clinical trials. Previously, she was EVP of Business Development at Intelect Medical (acquired by Boston Scientific), VP of Business Development at NDI Medical (now NDI Healthcare Fund), and held management positions at Medtronic. Juliana started as a management consultant with McKinsey & Company and as a financial auditor with Arthur Andersen. She presently serves as Board member of AdvaMed Accel, the medtech trade association’s smaller business division. Juliana holds an MBA from the Wharton Business School, University of Pennsylvania, and a Masters in Economics from Moscow State Institute of International Relations.
Christian S. Eversull, MD, Director, is co-founder and principal at AUST Development, a Mountain View, CA based design, development, and small-scale production firm with deep expertise relating to cardiovascular catheters. Chris has developed medical devices for the past 15 years working in various roles from design engineering to regulatory and clinical management. Prior to AUST, Chris held engineering positions at Medtronic AneuRx, Bacchus Vascular, and Acumen Medical. He is also a licensed internal medicine physician with a research focus in cardiovascular electrophysiology and holds undergraduate, masters, and medical degrees from Stanford University where he was awarded the Biodesign Innovation Fellowship and is presently Clinical Assistant Professor (Affiliated).
Hani N. Sabbah, Ph.D., F.A.C.C., F.A.H.A., Director, is tenured Professor of Medicine at Wayne State University, adjunct Professor of Medicine at the University of Maryland, and Visiting Professor of Medicine at Columbia University in New York, serves as a Director of Cardiovascular Research at the Henry Ford Health System in Detroit. Recognized globally for his basic and translational research in heart failure, his microembolization model for heart failure is considered a gold standard for dilated cardiomyopathies. He has been involved in the pre-clinical evaluation of a wide number of pharmaceutical, device, and biologic therapeutic candidates for heart failure.
Stefan D. Anker, MD, Ph.D., Scientific Advisory Board Director, is a German academic cardiologist and expert clinical trialist in heart failure, is presently Professor of Tissue Homeostasis in Cardiology & Metabolism at Berlin-Brandenburg Center for Regenerative Therapies at Charité Medical University of Berlin. He was previously Professor of Innovative Clinical Trials at University Hospital Göttingen and Professor of Cardiology & Cachexia Research at Charité. He served as Vice President of the European Society of Cardiology until 2018 and is Founding Editor-in-Chief of the Journal of ESC Heart Failure. In addition to his medical degree from Charité Medical School in Berlin, he obtained his PhD at the National Heart and Lung Institute of Imperial College London. He is recipient of numerous NIH and EU grants and awards including most recently the 2018 Copernicus Award from the German Research Foundation for his work on the pathophysiology of heart failure.
J. Alan Crunkleton, MD, Ph.D., Chief Operating Officer, is a medtech veteran whose hands-on experience spans all strategic and operational aspects of start-up companies from foundation to exit. He has a successful track record translating market needs and opportunities into products and rapidly establishing regulatory approvals, reimbursement channels, and global distribution. As CEO of Trifoil Imaging, he led the successful turnaround of this preclinical imaging company after founding and leading Correx, Inc., a minimally invasive aortic stenosis device company, and Boreas, Inc., a start-up that commercialized 4.2-Kelvin cryogenic cooler technology and was acquired by a global partner. Alan holds a Ph.D. in mechanical engineering from Massachusetts Institute of Technology as well as an MD from the University of Massachusetts.